Collegium Pharma (COLL) Reports Q4 Loss of $1.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
March 9, 2017 4:01 PM ESTXtampza® ER prescribed by more than 2,400 physicians since commercial launchONSOLIS® patent issued that extends patent protection until 2027Well capitalized with $153.2 million in cash and cash equivalents
CANTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter of 2016 and provided a corporate update.Â
We have made significant progress on the commercial launch of Xtampza ER. Through mid-February, more than 2,400 physicians have prescribed Xtampza ER, including 800 first time prescribers in 2017 alone, stated Michael Heffernan, Collegiums... More
